B. Pellae-Cosset
About
In The Last Decade
B. Pellae-Cosset
21 papers receiving 472 citations
Peers
Comparison fields: 5 of 45
- Oncology 244
- Pulmonary and Respiratory Medicine 234
- Pathology and Forensic Medicine 131
- Surgery 109
- Cancer Research 103
Countries citing papers authored by B. Pellae-Cosset
This map shows the geographic impact of B. Pellae-Cosset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Pellae-Cosset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Pellae-Cosset more than expected).
Fields of papers citing papers by B. Pellae-Cosset
This network shows the impact of papers produced by B. Pellae-Cosset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Pellae-Cosset. The network helps show where B. Pellae-Cosset may publish in the future.
Co-authorship network of co-authors of B. Pellae-Cosset
This figure shows the co-authorship network connecting the top 25 collaborators of B. Pellae-Cosset. A scholar is included among the top collaborators of B. Pellae-Cosset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Pellae-Cosset. B. Pellae-Cosset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 8 | |
| 3 | 2 | |
| 4 | 2 | |
| 5 | Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience. | 6 |
| 6 | 1 | |
| 7 | Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. | 24 |
| 8 | Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. | 16 |
| 9 | 81 | |
| 10 | [Carboplatin and urothelial tumors: review of the literature]. | 2 |
| 11 | [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes]. | 10 |
| 12 | 37 | |
| 13 | 86 | |
| 14 | 3 | |
| 15 | [Platinum derivatives in pediatric oncology]. | 2 |
| 16 | [Combination of chemotherapy (vindesine, lomustine, cisplatin, cyclophosphamide) and thoracic radiotherapy in nonresectable non-small cell bronchial carcinoma: final results of a phase II clinical trial]. | 1 |
| 17 | 32 | |
| 18 | 113 | |
| 19 | 32 | |
| 20 | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.